Neuronetics, Inc. (NASDAQ:STIM) Q3 2022 Earnings Conference Call November 8, 2022 8:30 AM ET Company Participants Mark Klausner - ICR Westwicke Keith Sullivan - President and Chief Executive Officer Stephen Furlong - Senior Vice President, Chief Financial Officer and Treasurer Conference Call Participants Adam Maeder - Piper Sandler Margaret Kaczor - William Blair Bill Plovanic - Canaccord Marie Thibault - BTIG Operator Good day and thank you for standing by. Welcome to the Neuronetics Report Third Quarter ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission File Number: 001-38546 NEURONETICS, INC. (Exact name of registrant as specified in its charter) incorporat ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ incorporation or organization) Delaware 33-1051425 (State or other jurisdiction of (I.R.S. Employer Identification No.) (A ...

Neuronetics Inc (NASDAQ:STIM) Q2 2022 Earnings Conference Call August 2, 2022 8:30 AM ET Company Participants Mark Klausner - Investor Relations Keith Sullivan - President & CEO Steve Furlong - SVP, CFO & Treasurer Conference Call Participants Adam Maeder - Piper Sandler Margaret Kaczor - William Blair William Plovanic - Canaccord Genuity Marie Thibault - BTIG David Turkaly - JMP Securities Operator Good day, and thank you for standing by. Welcome to the Neuronetics' Reports Second Quarter 2022 Financial an ...

TAP INTO A NEW POSSIBILITY for depression COMPANY PRESENTATION NASDAQ: STIM August 2022 Disclaimers neurostar.com This presentation contains estimates and other statistical data prepared by independent parties and by Neuronetics, Inc. (the "Company") relating to market size and growth and other data about the industry in which the Company operates. These estimates and data involve a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates and data. Certain stat ...

TAP INTO A NEW POSSIBILITY for depression COMPANY PRESENTATION NASDAQ: STIM May 2022 Disclaimers n e u r o s t a r . c o m This presentation contains estimates and other statistical data prepared by independent parties and by Neuronetics, Inc. (the "Company") relating to market size and growth and other data about the industry in which the Company operates. These estimates and data involve a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates and data. Cer ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission File Number: 001-38546 NEURONETICS, INC. (Exact name of registrant as specified in its charter) incorporation ...

Neuronetics, Inc. (NASDAQ:STIM) Q1 2022 Earnings Conference Call May 12, 2022 8:30 AM ET Company Participants Mark Klausner – Investor Relations Keith Sullivan – President and Chief Executive Officer Steve Furlong – Senior Vice President, Chief Financial Officer and Treasurer Conference Call Participants Adam Maeder – Piper Sandler Bill Plovanic – Canaccord Marie Thibault – BTIG Operator Good day, and thank you for standing by. Welcome to the Neuronetics First Quarter 2022 Financial and Operating Results Co ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission File Number: 001-38546 NEURONETICS, INC. (Exact name of registrant as specified in its charter) incorporation or or ...

Financial Data and Key Metrics Changes - Total revenue for Q4 2021 was $15 million, slightly down from $15.6 million in Q4 2020 [24] - U.S. NeuroStar Advanced Therapy revenue was $2.8 million, with a sequential growth of 8% over Q3 2021 [11] - U.S. treatment session revenue reached $11.2 million, a 2% increase year-over-year and a 10% increase sequentially [12] - Gross margin improved to 76.4% from 75.8% in the prior year, driven by higher average selling prices and a higher mix of treatment session revenues [26] - Operating expenses increased to $18.4 million, up $3.9 million compared to the prior year, primarily due to new marketing initiatives and personnel costs [27] - Net loss was $7.6 million or $0.29 per share, compared to a net loss of $3.7 million or $0.19 per share in 2020 [28] - EBITDA was negative $6.3 million, worsening from negative $2.4 million in 2020 [28] Business Line Data and Key Metrics Changes - The company shipped 48 systems in Q4 2021, up from 23, 36, and 40 systems in the previous three quarters [25] - Revenue per active site was approximately $12,200, compared to $12,100 in the prior year [26] Market Data and Key Metrics Changes - The company experienced a slower start in January 2022 due to Omicron, but trends improved in February [30] - The company anticipates year-over-year growth in each quarter of 2022, with a typical seasonal pattern expected [30] Company Strategy and Development Direction - The company has focused on overhauling its commercial organization and enhancing patient education to drive awareness of NeuroStar [9][22] - Exclusive commercial partnerships were established with three leading TMS providers, expected to have a material impact in 2022 [13] - The company plans to accelerate investments in sales, marketing, and R&D to support long-term growth [31] - The company aims to achieve EBIT breakeven by 2024 through moderated operating expense growth and accelerated top-line growth [32] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's position to execute its strategy despite challenges from the pandemic [36] - The company is focused on increasing awareness among customers and patients, optimizing its commercial organization, leveraging exclusive partnerships, and executing its clinical and regulatory strategy [37] - Management highlighted the importance of recent marketing initiatives and partnerships with influencers to drive awareness [40][41] Other Important Information - The company received 510(k) clearance for the MT Cap technology, which simplifies the motor threshold process for patients [18] - The company plans to launch a state-of-the-art training center, NeuroStar University, to educate practices on operationalizing their NeuroStar business [46] Q&A Session Summary Question: Guidance for 2022 revenue - Management provided guidance of $58 million to $62 million for 2022, with no staffing constraints impacting revenue [56][57] Question: Pipeline and indication expansion - The company expects FDA approval for OCD in Q2 2022, with other indications potentially following later [64][66] Question: Commercial strategy changes - Management discussed changes in marketing strategy to target a broader audience, including caregivers and family members [83] Question: Capital sales vs. leasing - The company is moving away from internally financing transactions and expects a decrease in leasing in 2022 [86] Question: Long-term growth outlook - Management expressed optimism about the company's strategy and investments, anticipating growth acceleration in 2023 and beyond [92][93]